(CDAX, Software/IT, CSH GR)



0.1 x

| Buy | (Hold) |
|------------------|---------------------|
| EUR 18.00 | (EUR 15.00) |
| Price Upside | EUR 12.95 39.0 % |

| Value Indicators: | EUR | |
|--------------------------|----------|--|
| DCF: | 17.80 | |
| FCF-Value Potential 24e: | 16.40 | |
| Peer group 24e: | 13.50 | |
| Market Snapshot: | EUR m | |
| Market cap: | 108.4 | |
| No. of shares (m): | 8.4 | |
| EV: | 115.8 | |
| Freefloat MC: | 76.9 | |
| Ø Trad. Vol. (30d): | 44.96 th | |
| | | |

| JR | Warburg ESG Risk Score: | 3.0 | Description: | |
|-------|-------------------------|---------|----------------------------|----------|
| 30 | ESG Score (MSCI based): | 3.0 | Description. | |
| 10 | Balance Sheet Score: | 5.0 | PLM and EIM specialist; wo | orldwide |
| | Market Liquidity Score: | 1.0 | biggest Dassault partner | |
| m | Shareholders: | | Key Figures (WRe): | 2022 |
| - 111 | Silarenoluers. | | Rey Figures (WRE). | 2022 |
| .4 | Freefloat | 71.00 % | Beta: | 1.2 |
| .4 | Primepulse | 29.00 % | Price / Book: | 3.5 > |
| .8 | | | Equity Ratio: | 36 % |
| .9 | | | Net Fin. Debt / EBITDA: | 0.0 |

M&A and diversification to drive growth and improve profitability

| Expected Figure | s Q4/2022: | | | | | |
|-----------------|--------------------|-------------|-------|-----------------|-------------|--------|
| in EUR m | Q4/22e | Q4/21 | yoy | 2022e | 2021 | yoy |
| Sales | 48.1 | 42.1 | 14.3% | 164.0 | 146.1 | 12.3% |
| EBIT margin | 3.9 8.0% | 3.8 9.0% | 1.4% | 6.4 3.9% | 6.2 4.3% | 3.2% |
| EPS in EUR | 0.30 | 0,31 | -3.2% | 0.45 | 0.51 | -11.8% |
| PLM | 36.6 | 35.8 | 2.0% | 134.5 | 130.0 | 3.5% |
| EIM | 7.8 | 6.3 | 24.3% | 25.7 | 16.0 | 60.3% |

Comment on Figures:

- Cenit is scheduled to report Q422 figures on 31 March
- Solid Q422 top-line growth is expected to lead Cenit to reaching the FY22 guidance

Net Debt / EBITDA:


 Q422 Profitability should have been impacted by one-off costs for changes in the personnel structure

Cenit recently acquired the Munich-based IBM specialist mip Management Information Partner. The transaction is a continuation of Cenit's **buy-and-build strategy** which was implemented by CEO Peter Schneck. The acquisition complements Cenit's existing EIM service portfolio especially in the fields of IBM-based information management and document logistics. While details of the deal were not disclosed, we expect mip sales to be about a low to mid single-digit million and assume the EBIT multiple to be mid-single-digit, which is below Cenit's valuation. Mip will be consolidated retroactively as of 1 January 2023.

As part of the Cenit 2025 strategy, management plans to **diversify Cenit's product portfolio** and reduce the dependence on Dassault. While the strategy includes decreasing the revenue share of third-party software, this does not mean that Cenit plans to scale back its partnership with Dassault as the platinum partner status has been defended. Rather, Cenit plans to expand its remaining business areas by acquiring two to three smaller companies per year in the fields of Digital Factory Solutions, SAP Solutions and Services. Another M&A focus is proprietary software which enlarges Cenit's product portfolio, strengthens its position as a one-stop-shop for digitalization, and serves as a **tailwind for margins**.

As management has recently highlighted, macro fears among its customer base are easing which **brightens the outlook for 2023**. Moreover, orders that were originally anticipated in Q4 2022 are expected to come in Q1 2023 – especially in the defence sector. The end of FY22 should have been impacted by macro uncertainties and muted sentiment for IT investment among Cenit's customers. Profitability is likely to have been burdened by costs for changes in the personnel structure. Several German IT companies have reported high levels of illness-related absence in Q4. Hence, staff shortages could have been a headwind. Our estimates for Cenit's Q4 22 as well as FY22 figures, which will be published on 31 March, are presented on the next page. Overall, the mid-term prospects look promising for Cenit, but FY22 figures might come in towards the lower end of guidance.

After rolling forward our model, the DCF-based **PT increases to EUR 18.00**. Given improving sentiment for IT investments, Cenit's potential for margin expansion as well as the upside to our PT, we upgrade the rating **from Hold to Buy**.




| Rel. Performance vs CDAX: | |
|---------------------------|---------|
| 1 month: | 1.3 % |
| 6 months: | -32.0 % |
| Year to date: | -5.7 % |
| Trailing 12 months: | 4.3 % |
| _ | |
| | |

| Company events: | |
|-----------------|---------|
| 31.03.23 | FY 2022 |
| 11.05.23 | Q1 |
| 17.05.23 | AGM |
| 01.08.23 | Q2 |

| FY End: 31.12. in EUR m | CAGR (22-24e) | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e |
|----------------------------|------------------|-------------|-------------|-----------|--------|--------|--------|--------|
| Sales | 7.9 % | 170.0 | 171.7 | 142.1 | 146.1 | 164.0 | 180.0 | 191.0 |
| Change Sales yoy | | 12.1 % | 1.0 % | -17.2 % | 2.8 % | 12.3 % | 9.8 % | 6.1 % |
| Gross profit margin | | 50.4 % | 49.8 % | 50.6 % | 53.0 % | 56.3 % | 56.0 % | 56.3 % |
| EBITDA | 14.3 % | 11.9 | 15.2 | 9.6 | 11.3 | 14.4 | 17.6 | 18.8 |
| Margin | | 7.0 % | 8.9 % | 6.8 % | 7.7 % | 8.8 % | 9.8 % | 9.9 % |
| EBIT | 28.1 % | 9.0 | 9.2 | 3.6 | 6.2 | 6.4 | 8.9 | 10.5 |
| Margin | | 5.3 % | 5.4 % | 2.6 % | 4.3 % | 3.9 % | 4.9 % | 5.5 % |
| Net income | 30.5 % | 5.9 | 6.9 | 2.3 | 4.3 | 3.7 | 5.3 | 6.4 |
| EPS | 30.0 % | 0.71 | 0.82 | 0.28 | 0.51 | 0.45 | 0.63 | 0.76 |
| EPS adj. | 30.0 % | 0.71 | 0.82 | 0.28 | 0.51 | 0.45 | 0.63 | 0.76 |
| DPS | 4.1 % | 0.60 | 0.00 | 0.47 | 0.75 | 0.60 | 0.65 | 0.65 |
| Dividend Yield | | 3.3 % | n.a. | 4.2 % | 5.3 % | 4.2 % | 5.0 % | 5.0 % |
| FCFPS | | 0.95 | 0.70 | 0.95 | 0.51 | 1.02 | 0.86 | 1.05 |
| FCF / Market cap | | 5.2 % | 5.1 % | 8.4 % | 3.6 % | 7.1 % | 6.6 % | 8.1 % |
| EV / Sales | | n.a. | 0.6 x | 0.5 x | 0.7 x | 0.8 x | 0.6 x | 0.6 x |
| EV / EBITDA | | n.a. | 6.8 x | 8.1 x | 9.0 x | 8.9 x | 6.6 x | 6.0 x |
| EV / EBIT | | n.a. | 11.3 x | 21.5 x | 16.3 x | 20.0 x | 13.1 x | 10.7 x |
| P/E | | 25.7 x | 16.5 x | 40.4 x | 27.8 x | 31.7 x | 20.6 x | 17.0 x |
| P / E adj. | | 25.7 x | 16.5 x | 40.4 x | 27.8 x | 31.7 x | 20.6 x | 17.0 x |
| FCF Potential Yield | | n.a. | 12.4 % | 10.3 % | 5.5 % | 6.8 % | 9.4 % | 10.4 % |
| Net Debt | | -17.9 | -17.0 | -24.5 | -25.0 | 1.8 | -0.3 | -3.6 |
| ROCE (NOPAT) | | 32.0 % | 31.9 % | 11.5 % | 22.6 % | 14.5 % | 14.5 % | 17.8 % |
| Guidance: 2 | 2022: sales El | JR 162-166n | n; EBIT EUR | 6.2-6.8m. | | | | |

Analyst






Company Background

- Cenit has evolved from an independent value-added software reseller to a system integrator providing complementary IT services and proprietary software.
- The business activities are divided into two segments: Product Lifecycle Management (PLM) and Enterprise Information Management (EIM).
- In the PLM segment, Cenit operates in the three business fields Dassault reselling and system integration, SAP-Dassault integration solutions and the proprietary software solution FastSuite.
- In the Enterprise Information Management (EIM) segment, Cenit implements document management and analytics software from IBM in addition to its add-on solutions.
- Cenit's fifth business field Digital Business Services provides application managed services, improving operational performance.

Competitive Quality

- Cenit is Dassault's biggest partner worldwide.
- Dassault's dominant market position in the PLM software market is reflected in its market share north of 30%, which lays the foundation for Cenit's competitive quality.
- Proprietary add-on software refines off-the-shelf products and provides bridges to industry standard software such as SAP S/4 HANA.
- The high level of industry expertise in verticals such as aerospace, discrete manufacturing and automotive underlines Cenit's reputation built up over 30 years.
- Cenit's M&A strategy is supported by the strong buy-and-build experience of CEO Peter Schneck and the extensive network of active anchor investor Primepulse.





| DCF model | | | | | | | | | | | | | | |
|-----------------------------|---------|-----------|----------|--------|--------|--------|--------|-----------|-----------|--------|--------|--------|--------|-------------|
| | Detaile | d forecas | t period | | | | 7 | ransition | al period | | | | | Term. Value |
| Figures in EUR m | 2022 | 2023e | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e | 2032e | 2033e | 2034e | |
| Sales | 164.0 | 180.0 | 191.0 | 198.6 | 206.6 | 214.2 | 221.7 | 229.0 | 236.1 | 242.8 | 249.1 | 255.0 | 260.7 | |
| Sales change | 12.3 % | 9.8 % | 6.1 % | 4.0 % | 4.0 % | 3.7 % | 3.5 % | 3.3 % | 3.1 % | 2.8 % | 2.6 % | 2.4 % | 2.2 % | 2.0 % |
| EBIT | 6.4 | 8.9 | 10.5 | 11.7 | 12.6 | 13.3 | 14.0 | 14.7 | 15.1 | 15.8 | 16.9 | 17.3 | 18.0 | |
| EBIT-margin | 3.9 % | 4.9 % | 5.5 % | 5.9 % | 6.1 % | 6.2 % | 6.3 % | 6.4 % | 6.4 % | 6.5 % | 6.8 % | 6.8 % | 6.9 % | |
| Tax rate (EBT) | 30.0 % | 30.0 % | 30.0 % | 30.0 % | 32.0 % | 32.0 % | 32.0 % | 32.0 % | 32.0 % | 32.0 % | 32.0 % | 32.0 % | 32.0 % | |
| NOPAT | 4.5 | 6.2 | 7.4 | 8.2 | 8.6 | 9.0 | 9.5 | 10.0 | 10.3 | 10.7 | 11.5 | 11.8 | 12.2 | |
| Depreciation | 8.0 | 8.7 | 8.3 | 8.3 | 7.9 | 8.1 | 8.0 | 7.8 | 8.0 | 8.3 | 8.5 | 8.7 | 8.9 | |
| in % of Sales | 4.9 % | 4.8 % | 4.3 % | 4.2 % | 3.8 % | 3.8 % | 3.6 % | 3.4 % | 3.4 % | 3.4 % | 3.4 % | 3.4 % | 3.4 % | |
| Changes in provisions | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Change in Liquidity from | | | | | | | | | | | | | | |
| - Working Capital | -0.5 | 2.0 | 1.3 | 1.0 | -3.6 | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | |
| - Capex | 0.9 | 2.1 | 2.0 | 1.9 | 2.1 | 2.6 | 3.1 | 3.2 | 4.3 | 4.4 | 5.0 | 5.1 | 6.3 | |
| Capex in % of Sales | 0.5 % | 1.2 % | 1.0 % | 1.0 % | 1.0 % | 1.2 % | 1.4 % | 1.4 % | 1.8 % | 1.8 % | 2.0 % | 2.0 % | 2.4 % | |
| - Other | 3.3 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | |
| Free Cash Flow (WACC Model) | 8.8 | 7.4 | 9.0 | 10.2 | 15.3 | 10.6 | 10.4 | 10.6 | 10.1 | 10.7 | 11.1 | 11.5 | 11.0 | 12 |
| PV of FCF | 0.0 | 7.4 | 8.3 | 8.7 | 12.0 | 7.7 | 7.0 | 6.6 | 5.8 | 5.7 | 5.4 | 5.2 | 4.6 | 72 |
| share of PVs | | 15.14 % | | | | | | 39.9 | 5 % | | | | | 44.91 % |

| Model parameter | | | | Valuation (m) | | | |
|---|---------|---------------------|------|----------------------------|-----|-----------------------|-------|
| Derivation of WACC: Debt ratio 20.00 % | | Derivation of Beta: | | Present values 2034e | 89 | | |
| | | | | Terminal Value | 72 | | |
| Debt ratio | 20.00 % | Financial Strength | 1.20 | Financial liabilities | 23 | | |
| Cost of debt (after tax) | 3.2 % | Liquidity (share) | 1.30 | Pension liabilities | 1 | | |
| Market return | 8.25 % | Cyclicality | 1.30 | Hybrid capital | 0 | | |
| Risk free rate | 2.75 % | Transparency | 1.10 | Minority interest | 10 | | |
| | | Others | 1.30 | Market val. of investments | 0 | | |
| | | | | Liquidity | 23 | No. of shares (m) | 8.4 |
| WACC | 8.29 % | Beta | 1.24 | Equity Value | 149 | Value per share (EUR) | 17.83 |

| Sensi | Sensitivity Value per Share (EUR) | | | | | | | | | | | | | | | | | |
|-------|-----------------------------------|--------|--------|--------|--------|--------|--------|--------|------|-------------------|---------|---------|---------|---------|---------|---------|---------|--|
| | Terminal Growth | | | | | | | | | Delta EBIT-margin | | | | | | | | |
| Beta | WACC | 1.25 % | 1.50 % | 1.75 % | 2.00 % | 2.25 % | 2.50 % | 2.75 % | Beta | WACC | -1.5 pp | -1.0 pp | -0.5 pp | +0.0 pp | +0.5 pp | +1.0 pp | +1.5 pp | |
| 1.47 | 9.3 % | 14.76 | 14.95 | 15.16 | 15.38 | 15.62 | 15.87 | 16.15 | 1.47 | 9.3 % | 11.66 | 12.90 | 14.14 | 15.38 | 16.62 | 17.87 | 19.11 | |
| 1.35 | 8.8 % | 15.76 | 16.00 | 16.25 | 16.52 | 16.81 | 17.12 | 17.46 | 1.35 | 8.8 % | 12.53 | 13.86 | 15.19 | 16.52 | 17.85 | 19.18 | 20.51 | |
| 1.30 | 8.5 % | 16.32 | 16.58 | 16.85 | 17.15 | 17.47 | 17.82 | 18.20 | 1.30 | 8.5 % | 13.02 | 14.39 | 15.77 | 17.15 | 18.53 | 19.91 | 21.28 | |
| 1.24 | 8.3 % | 16.91 | 17.20 | 17.50 | 17.83 | 18.19 | 18.58 | 19.00 | 1.24 | 8.3 % | 13.54 | 14.97 | 16.40 | 17.83 | 19.26 | 20.69 | 22.12 | |
| 1.18 | 8.0 % | 17.55 | 17.86 | 18.20 | 18.57 | 18.97 | 19.41 | 19.88 | 1.18 | 8.0 % | 14.11 | 15.59 | 17.08 | 18.57 | 20.06 | 21.55 | 23.03 | |
| 1.13 | 7.8 % | 18.23 | 18.58 | 18.96 | 19.37 | 19.82 | 20.31 | 20.85 | 1.13 | 7.8 % | 14.72 | 16.27 | 17.82 | 19.37 | 20.92 | 22.47 | 24.02 | |
| 1.01 | 7.3 % | 19.77 | 20.21 | 20.68 | 21.20 | 21.77 | 22.40 | 23.10 | 1.01 | 7.3 % | 16.13 | 17.82 | 19.51 | 21.20 | 22.89 | 24.59 | 26.28 | |

- We expect Cenit to increase margins going forward.
- The higher depreciation expense from leased objects in the detailed forecast period is adjusted for in Other.



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

| in EUR m | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e |
|--|--------|--------|--------|--------|--------|--------|--------|
| Net Income before minorities | n.a. | 7.0 | 2.3 | 4.4 | 4.2 | 5.9 | 7.0 |
| + Depreciation + Amortisation | n.a. | 6.0 | 6.0 | 5.0 | 8.0 | 8.7 | 8.3 |
| - Net Interest Income | n.a. | -0.3 | -0.2 | 0.3 | -0.5 | -0.5 | -0.5 |
| - Maintenance Capex | n.a. | 0.4 | 0.4 | 0.2 | 0.4 | 0.9 | 0.8 |
| + Other | n.a. | 0.0 | 0.0 | -3.4 | -3.5 | -3.3 | -3.3 |
| = Free Cash Flow Potential | n.a. | 12.9 | 8.1 | 5.6 | 8.8 | 10.9 | 11.7 |
| FCF Potential Yield (on market EV) | n/a | 12.4 % | 10.3 % | 5.5 % | 6.8 % | 9.4 % | 10.4 % |
| WACC | 8.29 % | 8.29 % | 8.29 % | 8.29 % | 8.29 % | 8.29 % | 8.29 % |
| = Enterprise Value (EV) | n.a. | 104.0 | 78.1 | 101.5 | 128.8 | 115.8 | 112.5 |
| = Fair Enterprise Value | n.a. | 155.2 | 97.4 | 67.4 | 106.0 | 131.2 | 141.6 |
| - Net Debt (Cash) | n.a. | 0.4 | 0.4 | 0.4 | 0.4 | -1.7 | -5.0 |
| - Pension Liabilities | n.a. | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 |
| - Other | n.a. | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Market value of minorities | n.a. | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 |
| + Market value of investments | n.a. | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| = Fair Market Capitalisation | n.a. | 145.6 | 87.8 | 57.8 | 96.4 | 123.7 | 137.5 |
| Number of shares, average | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 |
| = Fair value per share (EUR) | n.a. | 17.40 | 10.49 | 6.90 | 11.52 | 14.78 | 16.43 |
| premium (-) / discount (+) in % | | | | | | 14.2 % | 26.9 % |
| Sensitivity Fair value per Share (EUR) | | | | | | | |
| 11.29 | % n.a. | 12.47 | 7.40 | 4.76 | 8.15 | 10.62 | 11.93 |
| 10.29 9 | % n.a. | 13.79 | 8.23 | 5.34 | 9.06 | 11.73 | 13.14 |
| 9.29 | % n.a. | 15.40 | 9.24 | 6.04 | 10.16 | 13.09 | 14.61 |
| WACC 8.29 9 | | 17.40 | 10.49 | 6.90 | 11.52 | 14.78 | 16.43 |
| 7.29 9 | | 19.94 | 12.09 | 8.01 | 13.26 | 16.93 | 18.75 |
| 6.29 | | 23.30 | 14.20 | 9.46 | 15.55 | 19.77 | 21.82 |
| 5.29 9 | % n.a. | 27.92 | 17.10 | 11.47 | 18.71 | 23.68 | 26.04 |

Business model with low capex requirements and high FCF...

^{• ...}provides scope for acquisitions and a shareholder-friendly dividend policy.

FCF-Value-CAGR 2019-2025e: 1%

CENIT




| Valuation | | | | | | | |
|-------------------------------------|--------|--------|--------|--------|--------|--------|--------|
| | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024€ |
| Price / Book | 4.0 x | 2.8 x | 2.3 x | 2.8 x | 3.5 x | 3.1 x | 3.0 > |
| Book value per share ex intangibles | 2.90 | 3.30 | 3.70 | 3.90 | -0.15 | 0.35 | 0.90 |
| EV / Sales | n.a. | 0.6 x | 0.5 x | 0.7 x | 0.8 x | 0.6 x | 0.6 |
| EV / EBITDA | n.a. | 6.8 x | 8.1 x | 9.0 x | 8.9 x | 6.6 x | 6.0 x |
| EV / EBIT | n.a. | 11.3 x | 21.5 x | 16.3 x | 20.0 x | 13.1 x | 10.7 x |
| EV / EBIT adj.* | n.a. | 11.3 x | 21.5 x | 16.3 x | 14.1 x | 9.4 x | 8.3 x |
| P/FCF | 19.1 x | 19.5 x | 11.9 x | 27.6 x | 14.0 x | 15.1 x | 12.4 x |
| P/E | 25.7 x | 16.5 x | 40.4 x | 27.8 x | 31.7 x | 20.6 x | 17.0 x |
| P / E adj.* | 25.7 x | 16.5 x | 40.4 x | 27.8 x | 31.7 x | 20.6 x | 17.0 x |
| Dividend Yield | 3.3 % | n.a. | 4.2 % | 5.3 % | 4.2 % | 5.0 % | 5.0 % |
| FCF Potential Yield (on market EV) | n.a. | 12.4 % | 10.3 % | 5.5 % | 6.8 % | 9.4 % | 10.4 % |
| *Adjustments made for: - | | | | | | | |
| Company Specific Items | | | | | | | |
| | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024€ |
| Consulting and Service | 49.8 | 49.5 | 38.5 | 39.8 | 49.1 | 58.9 | 60.7 |
| Software | 15.4 | 16.5 | 15.9 | 17.7 | 20.5 | 22.0 | 25.9 |
| Third-party software | 104.3 | 105.6 | 87.4 | 88.5 | 93.0 | 94.4 | 95.4 |
| Merchandise | 0.5 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 |



| Consolidated profit & loss | | | | | | | |
|--|--------|--------|---------|--------|--------|--------|--------|
| In EUR m | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024 |
| Sales | 170.0 | 171.7 | 142.1 | 146.1 | 164.0 | 180.0 | 191.0 |
| Change Sales yoy | 12.1 % | 1.0 % | -17.2 % | 2.8 % | 12.3 % | 9.8 % | 6.1 % |
| Increase / decrease in inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Own work capitalised | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Sales | 170.0 | 171.7 | 142.1 | 146.1 | 164.0 | 180.0 | 191.0 |
| Material expenses | 84.2 | 86.3 | 70.3 | 68.6 | 71.7 | 79.2 | 83.5 |
| Gross profit | 85.8 | 85.5 | 71.9 | 77.5 | 92.3 | 100.8 | 107.5 |
| Gross profit margin | 50.4 % | 49.8 % | 50.6 % | 53.0 % | 56.3 % | 56.0 % | 56.3 % |
| Personnel expenses | 58.6 | 60.3 | 54.8 | 59.7 | 68.0 | 72.0 | 77.0 |
| Other operating income | 1.9 | 1.3 | 1.2 | 2.3 | 1.6 | 1.7 | 1.7 |
| Other operating expenses | 17.1 | 11.3 | 8.6 | 8.8 | 11.5 | 12.9 | 13.4 |
| Unfrequent items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA | 11.9 | 15.2 | 9.6 | 11.3 | 14.4 | 17.6 | 18.8 |
| Margin | 7.0 % | 8.9 % | 6.8 % | 7.7 % | 8.8 % | 9.8 % | 9.9 % |
| Depreciation of fixed assets | 1.1 | 4.3 | 4.4 | 4.1 | 4.5 | 4.5 | 4.5 |
| EBITA | 10.9 | 11.0 | 5.2 | 7.2 | 9.9 | 13.1 | 14.3 |
| Amortisation of intangible assets | 1.9 | 1.8 | 1.6 | 1.0 | 3.5 | 4.2 | 3.8 |
| Goodwill amortisation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT | 9.0 | 9.2 | 3.6 | 6.2 | 6.4 | 8.9 | 10.5 |
| Margin | 5.3 % | 5.4 % | 2.6 % | 4.3 % | 3.9 % | 4.9 % | 5.5 % |
| EBIT adj. | 9.0 | 9.2 | 3.6 | 6.2 | 9.1 | 12.3 | 13.5 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest expenses | 0.1 | 0.3 | 0.2 | 0.2 | 0.5 | 0.5 | 0.5 |
| Other financial income (loss) | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 |
| EBT | 9.0 | 8.9 | 3.4 | 6.5 | 5.9 | 8.4 | 10.1 |
| Margin | 5.3 % | 5.2 % | 2.4 % | 4.5 % | 3.6 % | 4.6 % | 5.3 % |
| Total taxes | 2.8 | 1.9 | 1.1 | 2.2 | 1.8 | 2.5 | 3.0 |
| Net income from continuing operations | 6.1 | 7.0 | 2.3 | 4.4 | 4.2 | 5.9 | 7.0 |
| Income from discontinued operations (net of tax) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income before minorities | 6.1 | 7.0 | 2.3 | 4.4 | 4.2 | 5.9 | 7.0 |
| Minority interest | 0.2 | 0.1 | 0.0 | 0.1 | 0.4 | 0.6 | 0.7 |
| Net income | 5.9 | 6.9 | 2.3 | 4.3 | 3.7 | 5.3 | 6.4 |
| Margin | 3.5 % | 4.0 % | 1.6 % | 2.9 % | 2.3 % | 2.9 % | 3.3 % |
| Number of shares, average | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 |
| EPS | 0.71 | 0.82 | 0.28 | 0.51 | 0.45 | 0.63 | 0.76 |
| EPS adj. | 0.71 | 0.82 | 0.28 | 0.51 | 0.45 | 0.63 | 0.76 |
| *Adjustments made for: | | | | | | | |

Guidance: 2022: sales EUR 162-166m; EBIT EUR 6.2-6.8m.

| Financial Ratios | | | | | | | |
|-------------------------------|---------|---------|---------|---------|---------|---------|---------|
| | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e |
| Total Operating Costs / Sales | 93.0 % | 91.1 % | 93.2 % | 92.3 % | 91.2 % | 90.2 % | 90.1 % |
| Operating Leverage | -2.5 x | 1.8 x | 3.5 x | 25.8 x | 0.3 x | 3.9 x | 3.1 x |
| EBITDA / Interest expenses | 168.3 x | 51.1 x | 47.5 x | 70.0 x | 28.9 x | 35.1 x | 37.7 x |
| Tax rate (EBT) | 31.6 % | 21.8 % | 33.2 % | 33.2 % | 30.0 % | 30.0 % | 30.0 % |
| Dividend Payout Ratio | 81.9 % | 0.0 % | 171.6 % | 144.1 % | 120.8 % | 92.9 % | 77.3 % |
| Sales per Employee | 226,502 | 232,986 | 199,900 | 213,242 | 184,063 | 198,895 | 208,288 |




Source: Walburg Nesearch Source: Walburg Nesear



| Consolidated balance sheet | | | | | | | |
|---|------|------|------|------|-------|-------|-------|
| In EUR m | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e |
| Assets | | | | | | | |
| Goodwill and other intangible assets | 13.5 | 12.2 | 11.1 | 10.3 | 35.2 | 32.0 | 29.1 |
| thereof other intangible assets | 1.6 | 1.3 | 0.9 | 0.6 | 0.2 | 0.4 | 0.5 |
| thereof Goodwill | 6.6 | 6.6 | 6.6 | 6.6 | 20.6 | 20.6 | 20.6 |
| Property, plant and equipment | 2.7 | 2.4 | 1.8 | 1.4 | 1.7 | 1.7 | 1.7 |
| Financial assets | 2.6 | 2.7 | 2.6 | 3.2 | 3.2 | 3.2 | 3.2 |
| Other long-term assets | 0.0 | 14.1 | 11.9 | 10.5 | 11.0 | 11.4 | 11.9 |
| Fixed assets | 18.7 | 31.4 | 27.3 | 25.4 | 51.1 | 48.3 | 45.9 |
| Inventories | 0.0 | 0.3 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 |
| Accounts receivable | 25.0 | 24.1 | 17.0 | 26.8 | 27.0 | 29.6 | 31.4 |
| Liquid assets | 18.0 | 18.5 | 26.1 | 26.4 | 22.6 | 24.7 | 28.0 |
| Other short-term assets | 17.3 | 15.1 | 13.0 | 14.2 | 14.2 | 14.2 | 14.2 |
| Current assets | 60.3 | 58.0 | 56.1 | 67.4 | 63.9 | 68.6 | 73.7 |
| Total Assets | 79.1 | 89.3 | 83.4 | 92.8 | 115.0 | 117.0 | 119.6 |
| Liabilities and shareholders' equity | | | | | | | |
| Subscribed capital | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 |
| Capital reserve | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 |
| Retained earnings | 14.1 | 14.2 | 14.2 | 14.5 | 12.0 | 12.2 | 13.2 |
| Other equity components | 14.3 | 16.2 | 18.4 | 19.0 | 12.5 | 13.2 | 14.0 |
| Shareholders' equity | 37.8 | 39.8 | 42.1 | 42.9 | 33.9 | 34.9 | 36.6 |
| Minority interest | 1.3 | 1.1 | 0.7 | 8.0 | 7.8 | 7.8 | 7.8 |
| Total equity | 39.1 | 40.9 | 42.7 | 43.6 | 41.7 | 42.7 | 44.4 |
| Provisions | 0.9 | 1.9 | 2.8 | 2.0 | 2.0 | 2.0 | 2.0 |
| thereof provisions for pensions and similar obligations | 0.1 | 1.5 | 1.6 | 1.4 | 1.4 | 1.4 | 1.4 |
| Financial liabilities (total) | 0.0 | 0.0 | 0.0 | 0.0 | 23.0 | 23.0 | 23.0 |
| Short-term financial liabilities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Accounts payable | 7.9 | 6.0 | 3.3 | 6.0 | 6.8 | 7.4 | 7.9 |
| Other liabilities | 31.1 | 40.5 | 34.7 | 41.2 | 41.5 | 41.9 | 42.3 |
| Liabilities | 40.0 | 48.4 | 40.7 | 49.2 | 73.3 | 74.3 | 75.2 |
| Total liabilities and shareholders' equity | 79.1 | 89.3 | 83.4 | 92.8 | 115.0 | 117.0 | 119.6 |


| Financial Ratios | | | | | | | |
|-------------------------------------|---------|---------|---------|---------|--------|--------|--------|
| | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e |
| Efficiency of Capital Employment | | | | | | | |
| Operating Assets Turnover | 9.9 x | 9.0 x | 10.9 x | 7.7 x | 8.7 x | 8.7 x | 8.6 x |
| Capital Employed Turnover | 8.0 x | 7.2 x | 7.8 x | 7.8 x | 3.8 x | 4.3 x | 4.7 x |
| ROA | 31.8 % | 21.9 % | 8.5 % | 16.7 % | 7.3 % | 10.9 % | 13.9 % |
| Return on Capital | | | | | | | |
| ROCE (NOPAT) | 32.0 % | 31.9 % | 11.5 % | 22.6 % | 14.5 % | 14.5 % | 17.8 % |
| ROE | 15.4 % | 17.7 % | 5.7 % | 10.0 % | 9.8 % | 15.4 % | 17.9 % |
| Adj. ROE | 15.4 % | 17.7 % | 5.7 % | 10.0 % | 9.8 % | 15.4 % | 17.9 % |
| Balance sheet quality | | | | | | | |
| Net Debt | -17.9 | -17.0 | -24.5 | -25.0 | 1.8 | -0.3 | -3.6 |
| Net Financial Debt | -18.0 | -18.5 | -26.1 | -26.4 | 0.4 | -1.7 | -5.0 |
| Net Gearing | -45.8 % | -41.5 % | -57.3 % | -57.2 % | 4.4 % | -0.8 % | -8.2 % |
| Net Fin. Debt / EBITDA | n.a. | n.a. | n.a. | n.a. | 2.9 % | n.a. | n.a. |
| Book Value / Share | 4.5 | 4.8 | 5.0 | 5.1 | 4.1 | 4.2 | 4.4 |
| Book value per share ex intangibles | 2.9 | 3.3 | 3.7 | 3.9 | -0.2 | 0.3 | 0.9 |





| Consolidated cash flow statement | | | | | | | |
|--|------|------|------|-------|-------|-------|-------|
| In EUR m | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e |
| Net income | 6.1 | 7.0 | 2.3 | 4.4 | 4.2 | 5.9 | 7.0 |
| Depreciation of fixed assets | 1.1 | 4.3 | 4.4 | 4.1 | 4.5 | 4.5 | 4.5 |
| Amortisation of goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Amortisation of intangible assets | 1.9 | 1.8 | 1.6 | 1.0 | 3.5 | 4.2 | 3.8 |
| Increase/decrease in long-term provisions | 0.0 | 0.7 | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 |
| Other non-cash income and expenses | -1.0 | -0.2 | 0.9 | -0.4 | 0.0 | 0.0 | 0.0 |
| Cash Flow before NWC change | 8.1 | 13.5 | 9.1 | 9.3 | 12.2 | 14.6 | 15.3 |
| Increase / decrease in inventory | 0.1 | -0.2 | 0.2 | 0.0 | -0.1 | 0.0 | 0.0 |
| Increase / decrease in accounts receivable | 4.5 | 3.0 | 9.0 | -11.4 | -0.2 | -2.6 | -1.8 |
| Increase / decrease in accounts payable | -3.1 | -4.6 | -6.0 | 10.3 | 8.0 | 0.6 | 0.5 |
| Increase / decrease in other working capital positions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Increase / decrease in working capital (total) | 1.5 | -1.9 | 3.2 | -1.1 | 0.5 | -2.0 | -1.3 |
| Net cash provided by operating activities [1] | 9.6 | 11.7 | 12.3 | 8.2 | 12.7 | 12.6 | 14.0 |
| Investments in intangible assets | -0.5 | -0.5 | -0.4 | -0.2 | -0.4 | -1.0 | -0.9 |
| Investments in property, plant and equipment | -1.1 | -2.0 | -0.4 | -0.4 | -0.5 | -1.1 | -1.1 |
| Payments for acquisitions | -0.2 | -0.1 | -0.1 | 0.0 | -29.0 | 0.0 | 0.0 |
| Financial investments | 2.0 | 0.1 | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 |
| Income from asset disposals | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net cash provided by investing activities [2] | -3.8 | -2.8 | -0.9 | -0.9 | -29.9 | -2.1 | -2.0 |
| Change in financial liabilities | 0.0 | 0.0 | 0.0 | 0.0 | 23.0 | 0.0 | 0.0 |
| Dividends paid | -8.4 | -5.0 | 0.0 | -3.9 | -6.3 | -5.0 | -5.4 |
| Purchase of own shares | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Capital measures | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other | -0.1 | -3.6 | -3.7 | -3.3 | -3.3 | -3.3 | -3.3 |
| Net cash provided by financing activities [3] | -8.5 | -8.6 | -3.7 | -7.2 | 13.4 | -8.3 | -8.7 |
| Change in liquid funds [1]+[2]+[3] | -2.7 | 0.3 | 7.7 | 0.1 | -3.8 | 2.2 | 3.3 |
| Effects of exchange-rate changes on cash | 0.2 | 0.1 | -0.1 | 0.2 | 0.0 | 0.0 | 0.0 |
| Cash and cash equivalent at end of period | 18.0 | 18.5 | 26.1 | 26.4 | 22.6 | 24.7 | 28.0 |

| Financial Ratios | | | | | | | |
|--------------------------------------|----------|---------|----------|-----------|---------|---------|---------|
| | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e |
| Cash Flow | | | | | | | |
| FCF | 8.0 | 5.8 | 8.0 | 4.3 | 8.5 | 7.2 | 8.8 |
| Free Cash Flow / Sales | 4.7 % | 3.4 % | 5.6 % | 2.9 % | 5.2 % | 4.0 % | 4.6 % |
| Free Cash Flow Potential | n.a. | 12.9 | 8.1 | 5.6 | 8.8 | 10.9 | 11.7 |
| Free Cash Flow / Net Profit | 134.3 % | 84.6 % | 343.7 % | 101.2 % | 226.7 % | 135.6 % | 137.1 % |
| Interest Received / Avg. Cash | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Interest Paid / Avg. Debt | n.a. | n.a. | n.a. | 16100.0 % | 4.3 % | 2.2 % | 2.2 % |
| Management of Funds | | | | | | | |
| Investment ratio | 1.0 % | 1.5 % | 0.6 % | 0.4 % | 0.5 % | 1.2 % | 1.0 % |
| Maint. Capex / Sales | n.a. | 0.3 % | 0.3 % | 0.1 % | 0.2 % | 0.5 % | 0.4 % |
| Capex / Dep | 55.7 % | 41.5 % | 13.4 % | 12.8 % | 11.3 % | 24.1 % | 24.1 % |
| Avg. Working Capital / Sales | 9.5 % | 9.1 % | 9.8 % | 9.9 % | 10.6 % | 10.1 % | 10.3 % |
| Trade Debtors / Trade Creditors | 315.4 % | 404.5 % | 520.8 % | 444.2 % | 397.1 % | 400.0 % | 397.5 % |
| Inventory Turnover | 2807.9 x | 334.3 x | 5855.7 x | 4573.0 x | 823.8 x | 910.3 x | 959.4 x |
| Receivables collection period (days) | 54 | 51 | 44 | 67 | 60 | 60 | 60 |
| Payables payment period (days) | 34 | 25 | 17 | 32 | 35 | 34 | 35 |
| Cash conversion cycle (Days) | 9 | 19 | 14 | 18 | 10 | 12 | 12 |



Source: Warburg Research Source: Warburg Research Source: Warburg Research



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5**% of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

| Company | Disclosure | Link to the historical price targets and rating changes (last 12 months) |
|---------|------------|--|
| CENIT | 5 | http://www.mmwarburg.com/disclaimer/disclaimer en/DE0005407100.htm |



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

| -B- | Buy: | The price of the analysed financial instrument is expected to rise over the next 12 months. |
|------------|-------------------|---|
| -H- | Hold: | The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months. |
| -S- | Sell: | The price of the analysed financial instrument is expected to fall over the next 12 months. |
| <u>"_"</u> | Rating suspended: | The available information currently does not permit an evaluation of the company. |

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING


| Rating | Number of stocks | % of Universe |
|------------------|------------------|---------------|
| Buy | 161 | 75 |
| Hold | 44 | 21 |
| Sell | 6 | 3 |
| Rating suspended | 3 | 1 |
| Total | 214 | 100 |

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

| Rating | Number of stocks | % of Universe |
|------------------|------------------|---------------|
| Buy | 44 | 86 |
| Hold | 6 | 12 |
| Sell | 0 | 0 |
| Rating suspended | 1 | 2 |
| Total | 51 | 100 |

PRICE AND RATING HISTORY CENIT AS OF 15.02.2023



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



| EQUITIES | | | |
|--|---|---|---|
| Matthias Rode Head of Equities | +49 40 3282-2678 mrode@mmwarburg.com | | |
| RESEARCH | | | |
| Michael Heider | +49 40 309537-280 | Hannes Müller | +49 40 309537-255 |
| Head of Research | mheider@warburg-research.com | Software, IT | hmueller@warburg-research.com |
| Henner Rüschmeier Head of Research | +49 40 309537-270 hrueschmeier@warburg-research.com | Andreas Pläsier Banks, Financial Services | +49 40 309537-246 aplaesier@warburg-research.com |
| Stefan Augustin Cap. Goods, Engineering | +49 40 309537-168 saugustin@warburg-research.com | Malte Schaumann Technology | +49 40 309537-170 mschaumann@warburg-research.com |
| Jan Bauer Renewables | +49 40 309537-155 jbauer@warburg-research.com | Oliver Schwarz Chemicals, Agriculture | +49 40 309537-250 oschwarz@warburg-research.com |
| Christian Cohrs Industrials & Transportation | +49 40 309537-175 ccohrs@warburg-research.com | Simon Stippig Real Estate, Telco | +49 40 309537-265 sstippig@warburg-research.com |
| Dr. Christian Ehmann | +49 40 309537-167 | Cansu Tatar | +49 40 309537-248 |
| BioTech, Life Science | cehmann@warburg-research.com | Cap. Goods, Engineering | ctatar@warburg-research.com |
| Felix Ellmann Software, IT | +49 40 309537-120 fellmann@warburg-research.com | Marc-René Tonn Automobiles, Car Suppliers | +49 40 309537-259 mtonn@warburg-research.com |
| Jörg Philipp Frey Retail, Consumer Goods | +49 40 309537-258 jfrey@warburg-research.com | Robert-Jan van der Horst Technology | +49 40 309537-290 rvanderhorst@warburg-research.com |
| Marius Fuhrberg Financial Services | +49 40 309537-185 | Andreas Wolf | +49 40 309537-140 |
| Mustafa Hidir | mfuhrberg@warburg-research.com +49 40 309537-230 | Software, IT | awolf@warburg-research.com |
| Automobiles, Car Suppliers | mhidir@warburg-research.com | | |
| Philipp Kaiser Real Estate. Construction | +49 40 309537-260 pkaiser@warburg-research.com | | |
| Thilo Kleibauer | +49 40 309537-257 | | |
| Retail, Consumer Goods | tkleibauer@warburg-research.com | | |
| INSTITUTIONAL EQUI | TY SALES | | |
| Marc Niemann | +49 40 3282-2660 | Christopher Seedorf | +49 40 3282-2695 |
| Head of Equity Sales, Germany Klaus Schilling | mniemann@mmwarburg.com +49 69 5050-7400 | Switzerland | cseedorf@mmwarburg.com |
| Head of Equity Sales, Germany | kschilling@mmwarburg.com | | |
| Tim Beckmann United Kingdom | +49 40 3282-2665 tbeckmann@mmwarburg.com | | |
| Lea Bogdanova | +49 69 5050-7411 | | |
| United Kingdom, Ireland | lbogdanova@mmwarburg.com | | |
| Jens Buchmüller Scandinavia, Austria | +49 69 5050-7415 jbuchmueller@mmwarburg.com | | |
| Matthias Fritsch | +49 40 3282-2696 | Sophie Hauer | +49 69 5050-7417 |
| United Kingdom | mfritsch@mmwarburg.com | Roadshow/Marketing | shauer@mmwarburg.com |
| Maximilian Martin Austria, Poland | +49 69 5050-7413 mmartin@mmwarburg.com | Juliane Niemann Roadshow/Marketing | +49 40 3282-2694 jniemann@mmwarburg.com |
| SALES TRADING | | <u> </u> | , , , |
| Oliver Merckel | +49 40 3282-2634 | Bastian Quast | +49 40 3282-2701 |
| Head of Sales Trading | omerckel@mmwarburg.com | Sales Trading | bquast@mmwarburg.com |
| Elyaz Dust | +49 40 3282-2702 | Jan-Philip Schmidt | +49 40 3282-2682 |
| Sales Trading Marcel Magiera | edust@mmwarburg.com +49 40 3282-2662 | Sales Trading Jörg Treptow | jschmidt@mmwarburg.com +49 40 3282-2658 |
| Sales Trading | mmagiera@mmwarburg.com | Sales Trading | jtreptow@mmwarburg.com |
| MACRO RESEARCH | | | |
| Carsten Klude Macro Research | +49 40 3282-2572 cklude@mmwarburg.com | Dr. Christian Jasperneite Investment Strategy | +49 40 3282-2439 cjasperneite@mmwarburg.com |
| Our research can be fo | ound under: | | |
| Warburg Research | research.mmwarburg.com/en/index.html | Refinitiv | www.refinitiv.com |
| Bloomberg | RESP MMWA GO | Capital IQ | www.capitaliq.com |
| FactSet | www.factset.com | | |
| | • | | |
| For access please conta | ct: | | |